Rockefeller Capital Management L.P. Buys 16,116 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Rockefeller Capital Management L.P. increased its position in Omnicell, Inc. (NASDAQ:OMCL) by 3.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 453,708 shares of the company’s stock after acquiring an additional 16,116 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Omnicell were worth $19,777,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of OMCL. Nisa Investment Advisors LLC increased its stake in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after acquiring an additional 1,000 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after purchasing an additional 553 shares during the last quarter. CWM LLC raised its stake in Omnicell by 68.2% in the second quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares in the last quarter. 1620 Investment Advisors Inc. lifted its position in Omnicell by 230.1% during the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the last quarter. Finally, Headlands Technologies LLC purchased a new position in Omnicell in the 2nd quarter worth approximately $104,000. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on OMCL shares. Craig Hallum lifted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Barclays upped their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. raised their price objective on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Bank of America reiterated a “neutral” rating and set a $57.00 price target (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Finally, StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a report on Wednesday, November 27th. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $52.00.

Omnicell Stock Performance

NASDAQ:OMCL opened at $46.59 on Monday. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The firm has a market cap of $2.16 billion, a PE ratio of -119.46, a price-to-earnings-growth ratio of 35.40 and a beta of 0.81. The business has a 50 day moving average price of $44.55 and a 200-day moving average price of $38.05.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.